LEAVITT PARTNERS, LLC

Lobbying for ORCHARD THERAPEUTICS NORTH AMERICA · Biopharmaceutical company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · Massachusetts · House · Senate · $20,000.00 income · posted Jan 12, 2026

Bills named in this filing 2

Lobbying activity 1

Health Issues

Newborn screening and pharmaceuticals. The Accelerating Kids Access to Care Act (H.R. 1509/S. 752).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.